Win the Market After the Patent Falls: ANDA and Suitability Petitions as Strategic Weapons
The patent cliff isn’t a cliff anymore—it’s a battlefield.
For years, the story was simple: once a drug’s patent expired, generic competition arrived and prices fell. But the modern reality is messier—and more strategic. The “win” after patent expira…
